VFDB - antivirulence drug (4S)-2-Chloro-4beta-(4-bromophenyl)-12-[[2-(methylthio)-3-pyridyl]carbonyl]-3,4,6,7,12,12balpha-hexahydroindolo[2,3-a]quinolizine-6alpha-carboxylic acid

Acinetobacter

Aeromonas

Anaplasma

Bacillus

Bartonella

Bordetella

Brucella

Burkholderia

Campylobacter

Chlamydia

Clostridium

Corynebacterium

Coxiella

Enterococcus

Escherichia

Francisella

Haemophilus

Helicobacter

Klebsiella

Legionella

Listeria

Mycobacterium

Mycoplasma

Neisseria

Pseudomonas

Rickettsia

Salmonella

Shigella

Staphylococcus

Streptococcus

Vibrio

Yersinia

(4S)-2-Chloro-4beta-(4-bromophenyl)-12-[[2-(methylthio)-3-pyridyl]carbonyl]-3,4,6,7,12,12balpha-hexahydroindolo[2,3-a]quinolizine-6alpha-carboxylic acid

Drug details:
Molecular formula: C₂₉H₂₃BrClN₃O₃S

Standard name: (4S,6S,12bR)-4-(4-bromophenyl)-2-chloro-12-(2-methylsulfanylpyridine-3-carbonyl)-4,6,7,12b-tetrahydro-3H-indolo[2,3-a]quinolizine-6-carboxylic acid

Classification: Pyridoindoles; Indoles and derivatives; Organoheterocyclic compounds; Organic compounds;

Curated SMILES: [H][C@]12C=C(Cl)C[C@@H](C3=CC=C(Br)C=C3)N1C(C(=O)O)CC1=C2N(C(=O)C2=CC=CN=C2SC)C2=C1C=CC=C2

Chemical structure:

Mycobacterium
Related VFcategory: Exoenzyme
Target: PtpB
Drug effect: Inhibits protein tyrosine phosphatase B (PtpB) to interfere with signal transduction pathways in macrophages.
Max phase: In vitro
Publication:
N�ren-M�ller A, et al., 2006. Discovery of protein phosphatase inhibitor classes by biology-oriented synthesis. Proc Natl Acad Sci U S A 103(28):10606-11.


	Back to Top

2004-2024 NIPB, CAMS&PUMC